Literature DB >> 12552075

Development of real-time PCR assays for the quantitative detection of Epstein-Barr virus and cytomegalovirus, comparison of TaqMan probes, and molecular beacons.

Jiska Jebbink1, Xin Bai, Beverly Barton Rogers, D Brian Dawson, Richard H Scheuermann, Rana Domiati-Saad.   

Abstract

Human Epstein-Barr virus (EBV) and cytomegalovirus (CMV) can cause serious complications in immunocompromised patients. Rapid diagnosis of EBV and CMV infection is critical in the management of the disease so that anti-viral therapy can be started early. Here we describe the development of real-time PCR assays using TaqMan probes and molecular beacons and compare the performance of both assays with a well-established, validated, gel-based PCR method for the quantification of EBV and CMV in patients' samples. The TaqMan and molecular beacon assays were linear between 10 to 10(7) viral genomes/reaction. Both assays generated calibration curves with strong correlation and low intra-assay and interassay variation. Results of EBV and CMV viral load determination inpatient samples obtained by the gel-based and real-time PCR were very similar. The real-time PCR assays showed increases in viral load before clinical measures of viral disease and decreases in viral load during anti-viral therapy in two of six pediatric patients. The data indicate that these TaqMan and molecular beacon approaches are accurate, rapid, and reliable assays for the diagnosis and monitoring of EBV and CMV infections in patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552075      PMCID: PMC1907370          DOI: 10.1016/S1525-1578(10)60446-1

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  23 in total

1.  Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients.

Authors:  A Humar; D Gregson; A M Caliendo; A McGeer; G Malkan; M Krajden; P Corey; P Greig; S Walmsley; G Levy; T Mazzulli
Journal:  Transplantation       Date:  1999-11-15       Impact factor: 4.939

2.  Development of a real-time quantitative assay for detection of Epstein-Barr virus.

Authors:  H G Niesters; J van Esser; E Fries; K C Wolthers; J Cornelissen; A D Osterhaus
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation.

Authors:  U Machida; M Kami; T Fukui; Y Kazuyama; M Kinoshita; Y Tanaka; Y Kanda; S Ogawa; H Honda; S Chiba; K Mitani; Y Muto; K Osumi; S Kimura; H Hirai
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

4.  High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders.

Authors:  F Baldanti; P Grossi; M Furione; L Simoncini; A Sarasini; P Comoli; R Maccario; R Fiocchi; G Gerna
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

5.  Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders.

Authors:  W J Jabs; H Hennig; M Kittel; K Pethig; F Smets; P Bucsky; H Kirchner; H J Wagner
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

6.  Predictive value of quantitative PCR-based viral burden analysis for eight human herpesviruses in pediatric solid organ transplant patients.

Authors:  X Bai; B B Rogers; P C Harkins; J Sommerauer; R Squires; K Rotondo; A Quan; D B Dawson; R H Scheuermann
Journal:  J Mol Diagn       Date:  2000-11       Impact factor: 5.568

7.  Clinical utility of a quantitative polymerase chain reaction for diagnosis of cytomegalovirus disease in solid organ transplant patients.

Authors:  A Ferreira-Gonzalez; R A Fisher; L A Weymouth; M R Langley; L Wolfe; D S Wilkinson; C T Garrett
Journal:  Transplantation       Date:  1999-10-15       Impact factor: 4.939

Review 8.  Cytomegalovirus reactivation in patients infected with HIV: the use of polymerase chain reaction in prediction and management.

Authors:  E F Bowen
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

9.  Early intervention in post-transplant lymphoproliferative disorders based on Epstein-Barr viral load.

Authors:  Y Hoshino; H Kimura; K Kuzushima; T Tsurumi; K Nemoto; A Kikuta; Y Nishiyama; S Kojima; T Matsuyama; T Morishima
Journal:  Bone Marrow Transplant       Date:  2000-07       Impact factor: 5.483

10.  Usefulness of quantitative real-time polymerase chain reaction in following up patients with Epstein-Barr virus infection after liver transplantation.

Authors:  T Orii; N Ohkohchi; H Kikuchi; N Koyamada; S Chubachi; S Satomi; H Kimura; Y Hoshino; M Morita
Journal:  Clin Transplant       Date:  2000-08       Impact factor: 2.863

View more
  15 in total

Review 1.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Validation of Roche LightCycler Epstein-Barr virus quantification reagents in a clinical laboratory setting.

Authors:  Margaret L Gulley; Hongxin Fan; Sandra H Elmore
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

3.  Relationship between the number of cytomegalovirus in anterior chamber and severity of anterior segment inflammation.

Authors:  Michiko Kandori; Dai Miyazaki; Keiko Yakura; Naoki Komatsu; Chizu Touge; Ryoko Ishikura; Yoshitsugu Inoue
Journal:  Jpn J Ophthalmol       Date:  2013-08-09       Impact factor: 2.447

Review 4.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

5.  Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.

Authors:  Miguel Islas-Ohlmayer; Angela Padgett-Thomas; Rana Domiati-Saad; Michael W Melkus; Petra D Cravens; Maria del P Martin; George Netto; J Victor Garcia
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

6.  Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).

Authors:  Sanford Kempin; Zhuoxin Sun; Neil E Kay; Elisabeth M Paietta; Joseph J Mazza; Rhett P Ketterling; Olga Frankfurt; David F Claxton; Joel N Saltzman; Gordan Srkalovic; Natalie S Callander; Gerald Gross; Martin S Tallman
Journal:  Acta Haematol       Date:  2019-07-23       Impact factor: 2.195

7.  Prevalence and risk factors for oral DNA tumor viruses in HIV-infected youth.

Authors:  Jessica A Kahn; Bret J Rudy; Jiahong Xu; Bill Kapogiannis; Elizabeth Secord; Maura Gillison
Journal:  J Med Virol       Date:  2016-05-09       Impact factor: 2.327

Review 8.  Laboratory assays for Epstein-Barr virus-related disease.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

9.  Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients.

Authors:  Mark A Jacobson; Dirk P Ditmer; Elizabeth Sinclair; Jeffrey N Martin; Steven G Deeks; Peter Hunt; Edward S Mocarski; Caroline Shiboski
Journal:  PLoS One       Date:  2009-04-17       Impact factor: 3.240

10.  Brain microbial populations in HIV/AIDS: α-proteobacteria predominate independent of host immune status.

Authors:  William G Branton; Kristofor K Ellestad; Ferdinand Maingat; B Matt Wheatley; Erling Rud; René L Warren; Robert A Holt; Michael G Surette; Christopher Power
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.